Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial

Abstract excerpt

<title>Abstract</title> <p><italic>HER2</italic> mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in <italic>HER2</italic>-mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib in patients with solid...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• Molecular Targeted Therapy
• Mutation, Missense
• Neoplasms
• Protein Kinase Inhibitors
• Quinolines
• Receptor, ErbB-2
• Receptor, ErbB-3

Identifiers and source

Literature Corpus work

42badf30-a791-5b49-9bf6-ef69abbb3c29

DOI

10.21203/rs.3.rs-1576467/v1